August 18, 2022
There was much discussion about current research in FAODs at our recent International Metabolic conference last month. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study.
Please join us for an update on the Reneo LC-FAOD study. Dr. Alex Dorenbaum, Chief Medical Officer at Reneo Pharmaceuticals will provide background about this clinical study and will answer your questions.